Swiss National Bank
TRVI icon

Swiss National Bank’s Trevi Therapeutics TRVI Stock Holding History

Swiss National Bank’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.01M Hold
168,200
– – ﹤0.01% 1848
2025
Q4 		$2.11M Buy
168,200
+6,500
+4% +$75.1K ﹤0.01% 1846
2025
Q3 		$1.48M Buy
+161,700
New +$1.21M ﹤0.01% 1993

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Swiss National Bank's TRVI Position: Q1 2026 in Review

Swiss National Bank held its Trevi Therapeutics (TRVI) position steady in Q1 2026 at 168,200 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

Swiss National Bank first reported a position in TRVI in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.11M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Swiss National Bank held 168,200 shares of Trevi Therapeutics worth $2.01M as of Q1 2026.
  • Swiss National Bank left its Trevi Therapeutics share count unchanged in Q1 2026.
  • Trevi Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1848 holding.
  • Swiss National Bank first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Swiss National Bank's Trevi Therapeutics position peaked at $2.11M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.